DK1931379T3 - Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme - Google Patents

Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme

Info

Publication number
DK1931379T3
DK1931379T3 DK06816196.7T DK06816196T DK1931379T3 DK 1931379 T3 DK1931379 T3 DK 1931379T3 DK 06816196 T DK06816196 T DK 06816196T DK 1931379 T3 DK1931379 T3 DK 1931379T3
Authority
DK
Denmark
Prior art keywords
proteins
producing
methods
well
same
Prior art date
Application number
DK06816196.7T
Other languages
English (en)
Inventor
Clifford C Shone
James A Crawford
Original Assignee
Sec Dep For Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sec Dep For Health filed Critical Sec Dep For Health
Application granted granted Critical
Publication of DK1931379T3 publication Critical patent/DK1931379T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06816196.7T 2005-10-07 2006-10-05 Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme DK1931379T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72427405P 2005-10-07 2005-10-07
US74290005P 2005-12-07 2005-12-07
PCT/US2006/038757 WO2007044382A2 (en) 2005-10-07 2006-10-05 Proteins with improved solubility and methods for producing and using same

Publications (1)

Publication Number Publication Date
DK1931379T3 true DK1931379T3 (da) 2013-08-19

Family

ID=37943335

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06816196.7T DK1931379T3 (da) 2005-10-07 2006-10-05 Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme

Country Status (4)

Country Link
US (2) US20090269358A1 (da)
EP (2) EP2471550A1 (da)
DK (1) DK1931379T3 (da)
WO (1) WO2007044382A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167119B1 (en) 2007-06-14 2016-08-24 The Secretary of State for Health Chemically modified peptides with improved immunogenicity
GB2456549A (en) * 2008-01-18 2009-07-22 Health Prot Agency Modified botulinum neurotoxin serotype E (BoNT/E) peptides
EP2890388A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
TR201910573T4 (tr) 2012-08-31 2019-08-21 Glaxosmithkline Biologicals Sa Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
EP3086809A4 (en) * 2013-12-24 2017-11-29 NovelMed Therapeutics, Inc. Compositions and methods of treating ocular diseases
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
EP0355460B1 (en) * 1988-08-24 2000-12-27 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5874238A (en) * 1993-02-26 1999-02-23 Immtech International Inc. Mutant protein and methods and materials for making and using it
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US6287566B1 (en) 1995-05-19 2001-09-11 The United States Of America As Represented By The Secretary Of The Army Protective peptides neurotoxin of C. botulinum
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6051239A (en) 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
GB9824282D0 (en) * 1998-11-05 1998-12-30 Microbiological Research Agenc Delivery of superoxide dismutase to neuronal cells
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US20040013687A1 (en) * 2002-05-31 2004-01-22 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US6764873B2 (en) * 2002-07-18 2004-07-20 International Business Machines Corporation Semiconductor wafer including a low dielectric constant thermosetting polymer film and method of making same
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen

Also Published As

Publication number Publication date
WO2007044382A2 (en) 2007-04-19
EP2471550A1 (en) 2012-07-04
EP1931379B1 (en) 2013-05-29
US8372405B2 (en) 2013-02-12
WO2007044382A3 (en) 2007-12-06
EP1931379A2 (en) 2008-06-18
US20120034239A1 (en) 2012-02-09
EP1931379A4 (en) 2009-10-21
US20090269358A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
DK1743027T3 (da) Mutantpneumolysinproteiner
DK1877090T3 (da) Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
DE602006005211D1 (de) HARQ-Verfahren und -System
DK2460550T3 (da) Injektionsindretning
LT2351578T (lt) Vakcinų gavimo būdas
DK1941026T3 (da) Fremgangsmåder til fremstilling af protein under anvendelse af anti-senescensforbindelser
DE502006007895D1 (de) Spannvorrichtung
DK2135603T3 (da) Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
DK1926582T3 (da) Fremgangsmåder til beredning af læder
EP1785697A4 (en) POSITION SENSOR
DE602006009573D1 (de) Vorspannungsschaltung
DK2314668T3 (da) Gen-inaktiverede mutanter med ændret proteinproduktion
DK1954713T3 (da) Modificerede grønfluorescerende proteiner og fremgangsmåder til anvendelse af samme
DE502005000334D1 (de) Spannvorrichtung
NO20055030D0 (no) Nivamaler
DK1864987T3 (da) Fremgangsmåder til fremstilling af 3-O-beskyttede morphinoner og 3-O-beskyttede morphinon-dienol-carboxylater
DE602006012689D1 (de) Überprüfungsverfahren
DK1768691T3 (da) Aequorinholdige præparater og fremgangsmåder til anvendelse af samme
DE502006002069D1 (de) Spannvorrichtung
DE112006003063A5 (de) Spannvorrichtung
DE602005006734D1 (de) Uhrwerk
EP1722013A4 (en) GALVANIZATION IN THE PRESENCE OF CO2
DE602005024247D1 (de) Spannvorrichtung
DK1943907T3 (da) Fremgangsmåde til fremstilling af kasein og indretning til anvendelse af fremgangsmåden